{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T05:19:53Z","timestamp":1792905593081,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Asymptomatic hyperuricemia was found to be associated with increased cardiovascular disease risk but the potential benefits of urate-lowering therapy (ULT) remain controversial. We conducted a systematic review and network meta-analysis (NMA) with frequentist model to estimate the efficacy and safety of ULT in asymptomatic hyperuricemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>MEDLINE, Embase, and Scopus were searched without language restrictions. Randomized controlled trials (RCT) of adults with asymptomatic hyperuricemia were eligible if they compared any pair of ULTs (i.e., allopurinol, febuxostat, probenecid, benzbromarone, sulfinpyrazone, rasburicase, lesinurad, and topiroxostat) and placebo or no ULT, and had outcomes of interest, including composite renal events, major adverse cardiovascular events, serum urate levels, estimated glomerular filtration rate (eGFR), systolic blood pressure, and adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>NMA with frequentist approach was applied to estimate relative treatment effects, i.e., risk ratio (RR) and mean difference (MD). A total of 23 RCTs were eligible. NMA identified beneficial effects of ULT on composite renal events and eGFR but not for other outcomes. Allopurinol and febuxostat had significantly lower composite renal events than placebo (RR 0.39, 95% confidence interval [CI] 0.23 to 0.66, and RR 0.68, 95% CI 0.46 to 0.99, respectively). Both treatments also resulted in significantly higher eGFR than placebo (MD 3.69\u00a0ml\/min\/1.73 m<jats:sup>2<\/jats:sup>, 95% CI 1.31 to 6.08, and MD 2.89\u00a0ml\/min\/1.73 m<jats:sup>2<\/jats:sup>, 95% CI 0.69 to 5.09, respectively). No evidence of inconsistency was identified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Evidence suggests that allopurinol and febuxostat are the ULTs of choice in reducing composite renal events and improving renal function.<\/jats:p>\n                <jats:p>Trial registration.<\/jats:p>\n                <jats:p>This study was registered with PROSPERO: CRD42019145908. The date of the first registration was 12<jats:sup>th<\/jats:sup> November 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-02850-3","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T14:03:36Z","timestamp":1655993016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"23","author":[{"given":"Tunlanut","family":"Sapankaew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlawat","family":"Thadanipon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narisa","family":"Ruenroengbun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamolpat","family":"Chaiyakittisopon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atiporn","family":"Ingsathit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawin","family":"Numthavaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"issue":"6","key":"2850_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"J FitzGerald","year":"2020","unstructured":"FitzGerald J, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles A. American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879\u201395.","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"2850_CR2","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"2850_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMcp1001124","volume":"364","author":"T Neogi","year":"2011","unstructured":"Neogi T. Clinical practice. Gout N Engl J Med. 2011;364(5):443\u201352.","journal-title":"Gout N Engl J Med"},{"issue":"12","key":"2850_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/jch.12855","volume":"18","author":"T Qin","year":"2016","unstructured":"Qin T, Zhou X, Wang J, Wu X, Li Y, Wang L, Huang H, Li J. Hyperuricemia and the Prognosis of Hypertensive Patients: A Systematic Review and Meta-Analysis. J Clin Hypertens. 2016;18(12):1268\u201378.","journal-title":"J Clin Hypertens"},{"key":"2850_CR5","doi-asserted-by":"crossref","unstructured":"Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, Li J. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PloS one. 2014;9(12):e114259.","DOI":"10.1371\/journal.pone.0114259"},{"key":"2850_CR6","first-page":"S1199","volume":"53","author":"F Braga","year":"2015","unstructured":"Braga F, Pasqualetti S, Ferraro S, Panteghini M. Hyperuricemia (HUA) as an independent risk factor for coronary heart disease (CHD) in the general population: A systematic review and meta-analysis. Clin Chem Lab Med. 2015;53:S1199.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"2850_CR7","doi-asserted-by":"publisher","first-page":"12403","DOI":"10.1038\/s41598-018-30321-z","volume":"8","author":"G Huang","year":"2018","unstructured":"Huang G, Xu R-H, Xu J-B, Liu Y, Liu Z-H, Xie X, Zhang T-J. Hyperuricemia is associated with atrial fibrillation prevalence in very elderly - a community based study in Chengdu. China Sci Rep. 2018;8(1):12403\u201312403.","journal-title":"China Sci Rep"},{"issue":"2","key":"2850_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2013.11.051","volume":"232","author":"M Li","year":"2014","unstructured":"Li M, Hou W, Zhang X, Hu L, Tang Z. Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. Atherosclerosis. 2014;232(2):265\u201370.","journal-title":"Atherosclerosis"},{"key":"2850_CR9","doi-asserted-by":"crossref","unstructured":"Xu X, Hu J, Song N, Chen R, Zhang T, Ding X. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrology. 2017;18(1):27.","DOI":"10.1186\/s12882-016-0433-1"},{"key":"2850_CR10","doi-asserted-by":"crossref","unstructured":"Sampson AL, Singer RF, Walters GD. Uric acid lowering therapies for preventing or delaying the\u00a0progression of chronic kidney disease. Cochrane Database Syst Rev. 2017;(10).","DOI":"10.1002\/14651858.CD009460.pub2"},{"issue":"1","key":"2850_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2369-15-122","volume":"15","author":"L Li","year":"2014","unstructured":"Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC nephrology. 2014;15(1):1\u20132.","journal-title":"BMC nephrology."},{"issue":"12","key":"2850_CR12","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","volume":"13","author":"D-H Kang","year":"2002","unstructured":"Kang D-H, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888\u201397.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2850_CR13","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008. Arthritis Rheum. 2011;63(10):3136\u201341.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2850_CR14","first-page":"1045","volume":"27","author":"KC Lin","year":"2000","unstructured":"Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu. Kinmen J Rheumatol. 2000;27(4):1045\u201350.","journal-title":"Kinmen J Rheumatol"},{"issue":"12","key":"2850_CR15","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/rheumatology\/kez196","volume":"58","author":"G Singh","year":"2019","unstructured":"Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. Rheumatology (Oxford). 2019;58(12):2177\u201380.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2850_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.arcmed.2006.03.008","volume":"37","author":"V Lohsoonthorn","year":"2006","unstructured":"Lohsoonthorn V, Dhanamun B, Williams MA. Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res. 2006;37(7):883\u20139.","journal-title":"Arch Med Res"},{"issue":"1","key":"2850_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"key":"2850_CR18","unstructured":"Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ, Levey AS. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.\u00a0Kidney Int Suppl. 2013;3(1):1\u201350."},{"issue":"12","key":"2850_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","volume":"30","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka H. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018\u201329.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"10","key":"2850_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.numecd.2019.06.016","volume":"29","author":"CW Liu","year":"2019","unstructured":"Liu CW, Chang WC, Lee CC, Shau WY, Hsu FS, Wang ML, Chen TC, Lo C, Hwang JJ. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia \u2013 A systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2019;29(10):1011\u201322.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"11","key":"2850_CR21","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/phar.2183","volume":"38","author":"JY Wu","year":"2018","unstructured":"Wu JY, Chang YT, Lin YC, Lee CH, Loh EW, Wu MY, Chang YS, Tam KW. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmacotherapy. 2018;38(11):1106\u201319.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2850_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.23876\/j.krcp.2017.36.3.274","volume":"36","author":"S Kim","year":"2017","unstructured":"Kim S, Kim HJ, Ahn HS, Oh SW, Han KH, Um TH, Cho CR, Han SY. Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis. Kidney Research and Clinical Practice. 2017;36(3):274\u201381.","journal-title":"Kidney Research and Clinical Practice"},{"issue":"1","key":"2850_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-015-0047-z","volume":"16","author":"T Kanji","year":"2015","unstructured":"Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC nephrology. 2015;16(1):1\u20139.","journal-title":"BMC nephrology."},{"issue":"6","key":"2850_CR24","first-page":"1008","volume":"40","author":"O Vinik","year":"2013","unstructured":"Vinik O, Wechalekar M, Buchbinder R, Van Der Heijde D, Bombardier C. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease and cardiovascular events: Systematic review. J Rheumatol. 2013;40(6):1008.","journal-title":"J Rheumatol"},{"key":"2850_CR25","doi-asserted-by":"publisher","first-page":"33082","DOI":"10.1038\/srep33082","volume":"6","author":"S Li","year":"2016","unstructured":"Li S, Yang H, Guo Y, Wei F, Yang X, Li D, Li M, Xu W, Li W, Sun L, et al. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Sci Rep. 2016;6:33082\u201333082.","journal-title":"Sci Rep"},{"issue":"2","key":"2850_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11255-012-0192-2","volume":"45","author":"AA Ejaz","year":"2013","unstructured":"Ejaz AA, Dass B, Lingegowda V, Shimada M, Beaver TM, Ejaz NI, Abouhamze AS, Johnson RJ. Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery. Int Urol Nephrol. 2013;45(2):449\u201358.","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"2850_CR27","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798\u2013810.","journal-title":"Am J Kidney Dis"},{"issue":"22","key":"2850_CR28","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","volume":"40","author":"S Kojima","year":"2019","unstructured":"Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H. Febuxostat for cerebral and cardiorenovascular events prevention study. Eur Heart J. 2019;40(22):1778\u201386.","journal-title":"Eur Heart J"},{"key":"2850_CR29","first-page":"563","volume":"17","author":"MNA Mukri","year":"2018","unstructured":"Mukri MNA, Kong W-Y, Mustafar R, Shaharir SS, Shah SA, Gafor AHA, Mohd R, Cader RA, Kamaruzaman L. Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial. EXCLI J. 2018;17:563.","journal-title":"EXCLI J"},{"key":"2850_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"2850_CR31","doi-asserted-by":"crossref","unstructured":"Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors): Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019): Cochrane; 2019.","DOI":"10.1002\/9781119536604"},{"key":"2850_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"issue":"1","key":"2850_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1536867X0900900103","volume":"9","author":"IR White","year":"2009","unstructured":"White IR. Multivariate Random-effects Meta-analysis. Stata J. 2009;9(1):40\u201356.","journal-title":"Stata J"},{"issue":"4","key":"2850_CR34","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/1536867X1501500403","volume":"15","author":"IR White","year":"2015","unstructured":"White IR. Network Meta-analysis. Stata J. 2015;15(4):951\u201385.","journal-title":"Stata J"},{"issue":"2","key":"2850_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/jrsm.1285","volume":"9","author":"BK G\u00fcnhan","year":"2018","unstructured":"G\u00fcnhan BK, Friede T, Held L. A design-by-treatment interaction model for network meta-analysis and meta-regression with integrated nested Laplace approximations. Research synthesis methods. 2018;9(2):179\u201394.","journal-title":"Research synthesis methods"},{"issue":"4","key":"2850_CR36","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, Salanti G. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082\u2013e1003082.","journal-title":"PLoS Med"},{"issue":"22","key":"2850_CR37","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","volume":"105","author":"W Doehner","year":"2002","unstructured":"Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105(22):2619\u201324.","journal-title":"Circulation"},{"issue":"1","key":"2850_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"Y-P Siu","year":"2006","unstructured":"Siu Y-P, Leung K-T, Tong MK-H, Kwan T-H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"2850_CR39","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.2215\/CJN.11451210","volume":"6","author":"M Kanbay","year":"2011","unstructured":"Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, Duranay M, Covic A, Johnson RJ. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6(8):1887\u201394.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"25","key":"2850_CR40","doi-asserted-by":"publisher","first-page":"e15962","DOI":"10.1097\/MD.0000000000015962","volume":"98","author":"G Ma","year":"2019","unstructured":"Ma G, Wang G, Xiao D, Teng W, Hui X, Ma G. Meta-analysis on allopurinol preventive intervention on contrast-induced acute kidney injury with random controlled trials: PRISMA. Medicine (Baltimore). 2019;98(25):e15962\u2013e15962.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2850_CR41","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","volume":"65","author":"M Goicoechea","year":"2015","unstructured":"Goicoechea M, de Vinuesa SG, Verdalles U, Verde E, Macias N, Santos A, de Jose AP, Cede\u00f1o S, Linares T, Lu\u00f1o J. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis. 2015;65(4):543\u20139.","journal-title":"Am J Kidney Dis"},{"key":"2850_CR42","doi-asserted-by":"crossref","unstructured":"Zeng XX, Tang Y, Hu K, Zhou X, Wang J, Zhu L, Liu J, Xu J. Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article. Medicine. 2018;97(13).","DOI":"10.1097\/MD.0000000000010161"},{"issue":"1","key":"2850_CR43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ehf2.12112","volume":"4","author":"J Zhang","year":"2017","unstructured":"Zhang J, Dierckx R, Mohee K, Clark AL, Cleland JG. Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta-analysis. ESC Heart Failure. 2017;4(1):40\u20135.","journal-title":"ESC Heart Failure"},{"issue":"1","key":"2850_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13075-016-1111-1","volume":"18","author":"JA Singh","year":"2016","unstructured":"Singh JA, Yu S. Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims. Arthritis Res Ther. 2016;18(1):209.","journal-title":"Arthritis Res Ther"},{"issue":"9732","key":"2850_CR45","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","volume":"375","author":"A Noman","year":"2010","unstructured":"Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161\u20137.","journal-title":"Lancet"},{"key":"2850_CR46","doi-asserted-by":"publisher","first-page":"27460","DOI":"10.1038\/srep27460","volume":"6","author":"L-L Kang","year":"2016","unstructured":"Kang L-L, Zhang D-M, Ma C-H, Zhang J-H, Jia K-K, Liu J-H, Wang R, Kong L-D. Cinnamaldehyde and allopurinol reduce fructose-induced cardiac inflammation and fibrosis by attenuating CD36-mediated TLR4\/6-IRAK4\/1 signaling to suppress NLRP3 inflammasome activation. Sci Rep. 2016;6:27460\u201327460.","journal-title":"Sci Rep"},{"issue":"1","key":"2850_CR47","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijcard.2012.05.083","volume":"160","author":"J He","year":"2012","unstructured":"He J, Yang Y, Peng D-Q. Monosodium urate (MSU) crystals increase gout associated coronary heart disease (CHD) risk through the activation of NLRP3 inflammasome. Int J Cardiol. 2012;160(1):72\u20133.","journal-title":"Int J Cardiol"},{"issue":"5","key":"2850_CR48","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3109\/08941939.2014.911395","volume":"27","author":"B Prieto-Moure","year":"2014","unstructured":"Prieto-Moure B, Carab\u00e9n-Reda\u00f1o A, Aliena-Valero A, Cejalvo D, Toledo AH, Flores-Bellver M, Mart\u00ednez-Gil N, Toledo-Pereyra LH, Lloris Carsi JM. Allopurinol in renal ischemia. J Invest Surg. 2014;27(5):304\u201316.","journal-title":"J Invest Surg"},{"key":"2850_CR49","doi-asserted-by":"publisher","first-page":"8575398","DOI":"10.1155\/2019\/8575398","volume":"2019","author":"GF Buys-Gon\u00e7alves","year":"2019","unstructured":"Buys-Gon\u00e7alves GF, Abreu LAS, Gregorio BM, Sampaio FJB, Pereira-Sampaio MA, de Souza DB. Antioxidants as Renoprotective Agents for Ischemia during Partial Nephrectomy. Biomed Res Int. 2019;2019:8575398.","journal-title":"Biomed Res Int"},{"issue":"8","key":"2850_CR50","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00210-016-1260-4","volume":"389","author":"D Steubl","year":"2016","unstructured":"Steubl D, Michel MC. Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(8):815\u20137.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"2850_CR51","first-page":"1209","volume":"4","author":"M Hu","year":"2008","unstructured":"Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag. 2008;4(6):1209\u201320.","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"2850_CR52","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10157-014-1012-z","volume":"19","author":"D Bayram","year":"2015","unstructured":"Bayram D, Sezer MT, Inal S, Altunta\u015f A, K\u0131d\u0131r V, Orhan H. The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. Clin Exp Nephrol. 2015;19(3):443\u20139.","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"2850_CR53","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s10157-018-1652-5","volume":"23","author":"X Liu","year":"2019","unstructured":"Liu X, Wang H, Ma R, Shao L, Zhang W, Jiang W, Luo C, Zhai T, Xu Y. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3\u20135. Clin Exp Nephrol. 2019;23(3):362\u201370.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"2850_CR54","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4103\/0971-4065.114499","volume":"23","author":"BS Pai","year":"2013","unstructured":"Pai BS, Swarnalatha G, Ram R, Dakshinamurty K. Allopurinol for prevention of progression of kidney disease with hyperuricemia. Indian journal of nephrology. 2013;23(4):280.","journal-title":"Indian journal of nephrology"},{"key":"2850_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7812\/TPP\/17-142","volume":"22","author":"G Levy","year":"2018","unstructured":"Levy G, Shi JM, Cheetham TC, Rashid N. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease. Perm J. 2018;22:17\u2013142.","journal-title":"Perm J."},{"issue":"1","key":"2850_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCHEARTFAILURE.109.868604","volume":"3","author":"K Ogino","year":"2010","unstructured":"Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010;3(1):73\u201381.","journal-title":"Circ Heart Fail."},{"issue":"11","key":"2850_CR57","first-page":"1039","volume":"17","author":"M Jalalzadeh","year":"2012","unstructured":"Jalalzadeh M, Nurcheshmeh Z, Mohammadi R, Mousavinasab N, Ghadiani MH. The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia. Journal of research in medical sciences. 2012;17(11):1039.","journal-title":"Journal of research in medical sciences"},{"key":"2850_CR58","doi-asserted-by":"crossref","unstructured":"Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). 2013;77(8):2043\u20139.","DOI":"10.1253\/circj.CJ-13-0082"},{"issue":"2","key":"2850_CR59","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000355621","volume":"23","author":"AA Taheraghdam","year":"2014","unstructured":"Taheraghdam AA, Sharifipour E, Pashapour A, Namdar S, Hatami A, Houshmandzad S, Sadeghihokmabadi E, Tazik M, Rikhtegar R, Mahmoodpoor A. Allopurinol as a preventive contrivance after acute ischemic stroke in patients with a high level of serum uric acid: a randomized, controlled trial. Med Princ Pract. 2014;23(2):134\u20139.","journal-title":"Med Princ Pract"},{"issue":"4","key":"2850_CR60","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/cen.12673","volume":"83","author":"P Liu","year":"2015","unstructured":"Liu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clin Endocrinol. 2015;83(4):475\u201382.","journal-title":"Clin Endocrinol"},{"issue":"6","key":"2850_CR61","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","volume":"66","author":"D Sircar","year":"2015","unstructured":"Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66(6):945\u201350.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"2850_CR62","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/JIM.0000000000000242","volume":"63","author":"M Takir","year":"2015","unstructured":"Takir M, Kostek O, Ozkok A, Elcioglu OC, Bakan A, Erek A, Mutlu HH, Telci O, Semerci A, Odabas AR. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 2015;63(8):924\u20139.","journal-title":"J Investig Med"},{"key":"2850_CR63","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ijcme.2015.07.001","volume":"8","author":"A Nakagomi","year":"2015","unstructured":"Nakagomi A, Saiki Y, Noma S, Kohashi K, Morisawa T, Kosugi M, Kusama Y, Atarashi H, Shimizu W. Effects of febuxostat and allopurinol on the inflammation and cardiac function in chronic heart failure patients with hyperuricemia. IJC Metabolic & Endocrine. 2015;8:46\u201355.","journal-title":"IJC Metabolic & Endocrine"},{"issue":"12","key":"2850_CR64","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40261-015-0349-8","volume":"35","author":"S Tani","year":"2015","unstructured":"Tani S, Nagao K, Hirayama A. Effect of febuxostat, a xanthine oxidase inhibitor, on cardiovascular risk in hyperuricemic patients with hypertension: a prospective, open-label, pilot study. Clin Drug Investig. 2015;35(12):823\u201331.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"2850_CR65","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/hdi.12313","volume":"19","author":"Y Tsuruta","year":"2015","unstructured":"Tsuruta Y, Kikuchi K, Tsuruta Y, Sasaki Y, Moriyama T, Itabashi M, Takei T, Uchida K, Akiba T, Tsuchiya K. Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: a randomized controlled study. Hemodial Int. 2015;19(4):514\u201320.","journal-title":"Hemodial Int"},{"key":"2850_CR66","doi-asserted-by":"publisher","first-page":"205435811667534","DOI":"10.1177\/2054358116675343","volume":"3","author":"S Beddhu","year":"2016","unstructured":"Beddhu S, Filipowicz R, Wang B, Wei G, Chen X, Roy AC, DuVall SL, Farrukh H, Habib AN, Bjordahl T. A randomized controlled trial of the effects of febuxostat therapy on adipokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy. Can J Kidney Health Dis. 2016;3:2054358116675343.","journal-title":"Can J Kidney Health Dis"},{"key":"2850_CR67","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ijcard.2016.09.073","volume":"224","author":"S Kojima","year":"2016","unstructured":"Kojima S, Kojima S, Hifumi A, Soejima H, Ogawa H. Therapeutic strategy for efficient reduction of serum uric acid levels with allopurinol versus benzbromarone in hyperuricemic patients with essential hypertension\u2014A randomized crossover study (terao study). Int J Cardiol. 2016;224:437\u20139.","journal-title":"Int J Cardiol"},{"issue":"4","key":"2850_CR68","first-page":"286","volume":"11","author":"S Golmohammadi","year":"2017","unstructured":"Golmohammadi S, Almasi A, Manouchehri M, Omrani HR, Zandkarimi MR. Allopurinol against progression of chronic kidney disease. Iran J Kidney Dis. 2017;11(4):286.","journal-title":"Iran J Kidney Dis"},{"issue":"5","key":"2850_CR69","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2215\/CJN.10771016","volume":"12","author":"CJ McMullan","year":"2017","unstructured":"McMullan CJ, Borgi L, Fisher N, Curhan G, Forman J. Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: a randomized controlled trial. Clin J Am Soc Nephrol. 2017;12(5):807\u201316.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2850_CR70","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1681\/ASN.2016050521","volume":"28","author":"DI Jalal","year":"2017","unstructured":"Jalal DI, Decker E, Perrenoud L, Nowak KL, Bispham N, Mehta T, Smits G, You Z, Seals D, Chonchol M. Vascular function and uric acid-lowering in stage 3 CKD. J Am Soc Nephrol. 2017;28(3):943\u201352.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02850-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02850-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02850-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T18:04:10Z","timestamp":1668449050000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02850-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02850-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"14 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}